摘要
干扰素调节因子(IRF)家族包括参与多种生物学过程调控的转录因子。最初被确定为I型干扰素系统的转录调节, IRFs 在适应性免疫,分化和肿瘤发生的细胞生长中发挥了举足轻重的作用。因此,了解IRF的生物学在癌症的发展和进展中宿主反应有十分重要的意义。许多证据表明,不同的IRFs都参与了慢性粒细胞白血病(CML)发病机制中的作用,一种由骨髓增生性疾病的BCR-ABL蛋白引起的失控。BCR-ABL酪氨酸激酶的活性有利于构成细胞的增殖显示,抑制细胞凋亡,使细胞生存在细胞外基质的粘附不恰当。不同的BCR-ABL酪氨酸激酶抑制剂目前被用于慢性粒细胞白血病的治疗。这些药物能够产生长达八年的慢性粒细胞白血病,其特定的总生存率> 90%,只有少数患者会产生药物停药的分子反应。因此,有一个未符合需要的额外的治疗目标,可能会导致大多数患者被诊断为慢性粒细胞白血病痊愈。越来越多的证据表明在CML发病机制中有IRF4和 IRF8两个作用。此外,IRF1是持续在白血病和脊髓发育不良患者中一个或两个等位基因中被删除的。最后,我们发现IRF5是BCR-ABL激酶活性的靶标,并且可以减少慢性粒细胞白血病细胞的增殖。在这篇文章中,我们提供了IRFs对慢性粒细胞白血病作用的更新。
关键词: IRFs;BCR-ABL;CML;造血;细胞增殖;基因调控。
Current Cancer Drug Targets
Title:Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia
Volume: 16 Issue: 7
Author(s): Livia Manzella, Elena Tirrò, Maria Stella Pennisi, Michele Massimino, Stefania Stella, Chiara Romano, Silvia Rita Vitale and Paolo Vigneri
Affiliation:
关键词: IRFs;BCR-ABL;CML;造血;细胞增殖;基因调控。
摘要: The Interferon Regulatory Factor (IRF) family consists of multiple transcription factors involved in the regulation of a variety of biological processes. Originally identified as transcriptional regulators of the type I interferon system, IRFs play a pivotal role in adaptive immunity, cell growth, differentiation and tumorigenesis. Hence, understanding IRF biology has important implications in the host response to cancer development and progression. Many lines of evidence suggest that different IRFs are involved in the pathogenesis of Chronic Myeloid Leukemia (CML), a myeloproliferative disorder caused by the BCR-ABL oncoprotein. BCR-ABL displays constitutive tyrosine kinase activity that favors cell proliferation, inhibits apoptosis and allows cell survival even in the absence of proper adhesion to the extracellular matrix. Different BCR-ABL tyrosine kinase inhibitors are currently available for CML treatment. These drugs are able to generate eight year CML-specific overall survival rates >90%, only a minority of patients will achieve molecular responses compatible with drug discontinuation. Thus, there is an unmet need for additional therapeutic targets that may lead to the cure of most patients diagnosed with CML. A growing body of evidence has suggested a role for both IRF4 and IRF8 in the pathogenesis of CML. Furthermore, IRF1 is consistently deleted at one or both alleles in patients with leukemia and myelodysplasia. Finally, we have recently demonstrated that IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. In this article, we provide an update on the current knowledge of the role of the IRFs in CML.
Export Options
About this article
Cite this article as:
Livia Manzella, Elena Tirrò, Maria Stella Pennisi, Michele Massimino, Stefania Stella, Chiara Romano, Silvia Rita Vitale and Paolo Vigneri , Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia, Current Cancer Drug Targets 2016; 16 (7) . https://dx.doi.org/10.2174/1568009616666160105105857
DOI https://dx.doi.org/10.2174/1568009616666160105105857 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
Current Alzheimer Research Immune System, Cell Senescence, Aging and Longevity - Inflamm-Aging Reappraised
Current Pharmaceutical Design Cytokine Analysis in Patients with Different Stages of Thromboangiitis Obliterans
Current Molecular Medicine Wasp Venom Toxins as a Potential Therapeutic Agent
Protein & Peptide Letters Pathogenesis of Diabetic Retinopathy and Diabetic Macular Edema and Enzyme Inhibition
Current Enzyme Inhibition Chemical Crosslinking: Role in Protein and Peptide Science
Current Protein & Peptide Science 3D Cell and Scaffold Patterning Strategies in Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Current Vascular Pharmacology Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Genetic Approaches for Antigen-Selective Cell Therapy
Current Gene Therapy Current Trend and Pro-survival Approaches for Augmenting Stem Cell Viability
Current Pharmaceutical Biotechnology Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Bone Tissue Engineering – A Field For New Medicinal Products?
Current Pharmaceutical Biotechnology Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design Neuroprotection: The Emerging Concept of Restorative Neural Stem Cell Biology for the Treatment of Neurodegenerative Diseases
Current Neuropharmacology